PepEvolutionSurvodutide
Boehringer Ingelheim's dual GLP-1/glucagon agonist in phase-3 for obesity and MASH — strong phase-2 signal.
Verdict — C · Emerging / Mixed
A differentiated mechanism with strong phase-2 data in obesity and MASH, but no approval and no verified source. A C pending SYNCHRONIZE readout.
Overview
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist in phase-3 SYNCHRONIZE trials for obesity and metabolic-associated steatohepatitis (MASH). Phase-2 data showed approximately 19% weight loss. MASH is an area of significant unmet need and the glucagon axis adds hepatic benefit beyond GLP-1 alone. No approval exists; no verified gray-market supply.
PepScore Breakdown — the four axes
Evidence
35% weightHow strong is the published human science?
Sourcing & COA
30% weightOur moatCan a buyer obtain an independently-verified, high-purity version? — our proprietary layer.
Safety & Risk
25% weightWhat is the real-world harm potential?
Practicality
10% weightHow easy is it to actually run a verified version?
Sources & Citations
Every claim cites a primary source. Citations are machine-audited against NCBI — see methodology.
Educational only — not medical advice. PepScore is an educational research grade, not a prescription or dosing recommendation. Some vendor links are affiliate links — this never affects grades. Consult a licensed healthcare provider before using any compound.